secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0000950170-24-135212
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics reports interim Phase 1 data for PRT2527; plans to partner CDK9 program
--------------------------------------------------------------------------------

- PRT2527 monotherapy ORR 17.4% (4/23 evaluable); combination with zanubrutinib ORR 38.5% (5/13 evaluable).
- CRs observed in DLBCL (monotherapy and combo) and MCL (combo); responses in patients with prior CAR-T therapy.
- Most common TEAE: neutropenia (48%, grade≥3: 46%); one DLT of tumor lysis syndrome at 24 mg/m2 dose.
- Prelude will seek a partner for PRT2527 to focus resources on SMARCA degrader programs.
- Data presented at 66th ASH Annual Meeting on Dec 11, 2024; 46 patients safety-evaluable as of Sep 17, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/0000950170-24-135212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024135212/prld-20241211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-135212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer